Sep 12, 2023 / 12:50PM GMT
Patrick Andrew Wood -
Amazing. Thank you so much and welcome, everyone. Before we start, I get the fun disclosures, morganstanley.com/researchdisclosures. I'm just timing this right down, go there. I'm sure you all will, or you can reach out to your MS sales rep. Patrick Wood, U.S. med tech team. And welcome, everyone. Big thank you, of course, the entire BD team. Obviously, we've got Chris, we've got Mike, and we got Dave across the Head of Medical segment, across Life Sciences and of course, as CFO. Thank you so much for joining us and agreeing to do this.
Questions and Answers:
Patrick Andrew Wood -Well, we'll we kick off with, how about 2024 margins? You guys are running a little bit ahead, I would say. See how the year closes, but maybe where you were hoping to be on the margin structure side of things. How are you thinking about the interplay between reinvestment and margins going forward?
Christopher J. DelOrefice - Becton, Dickinson and Company - Executive VP & CFO
Yes, yes. No, I appreciate the question. Thanks